Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, Xiaodong Fang et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry PerspectiveHardik Mody, Vijay Upreti, Swati Gupta et al.|Clinical Pharmacology & Therapeutics|2023Cited by 26
PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position PaperUma Kavita, Nagendra Chemuturi, Vijay Upreti et al.|The AAPS Journal|2023Cited by 17
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies DevelopmentJochem Gokemeijer, Vibha Jawa, Nanda Balasubramanian et al.|Clinical Pharmacology & Therapeutics|2023Cited by 9
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer TherapyPrathap Nagaraja Shastri, Alison Betts, Meric Ovacik et al.|Clinical Pharmacology & Therapeutics|2024Cited by 9